Spexis, NewAmsterdam, Molecure, and Cyclo Therapeutics: Key Updates in Biopharmaceutical Industry

Spexis AG announces changes to its Executive Committee, with Hernan Levett stepping down as Chief Financial Officer and Martin Jakobovic replacing him. NewAmsterdam Pharma appoints Ian Somaiya as Chief Financial Officer. Molecure reports significant financial and operational momentum, raising CHF 17.8 million in a secondary public offering and receiving FDA approval for clinical trials. Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. enter into a definitive merger agreement.